Inari, now part of Stryker

Built on a strong foundation of innovation, high-quality products and rigorous clinical evidence, Inari became one of the defining forces in venous care. Now, as Stryker’s Peripheral Vascular business, that foundation has everything it needs to go further. We lead fearlessly, with a portfolio that spans the treatment of venous and arterial diseases. We innovate intentionally, designing technology alongside clinicians. And we transform together, expanding access, deepening expertise and raising the standard of care globally. Introducing Stryker Peripheral Vascular. Purpose-built technology. Patient-centered solutions. Follow us on LinkedIn: bit.ly/4tkdQ1T Follow us on Instagram: bit.ly/4tvcT6i #StrykerPV #PeripheralVascular #MedTech #SIR2026 #TogetherWithOurCustomers The information in this post is intended for healthcare professionals in the United States only.

Our shared global commitment to our mission has enabled us to return to full operations across our manufacturing network. Patient care remains our highest priority, with a continued focus on supporting healthcare providers and the patients they serve. Read more: stryker.com/us/en/about/ne…

March is Blood Clot Awareness Month! Venous thromboembolism (#VTE)—including deep vein thrombosis (#DVT) and pulmonary embolism (#PE)—remains a significant clinical challenge across care settings. Early recognition, timely diagnosis, and informed treatment decisions play an important role in patient care. Together, let’s raise awareness around blood clots and support continued education focused on improving outcomes for patients at risk of VTE. #BloodClotAwarenessMonth #BCAM #VTE #PulmonaryEmbolism #DVT #TogetherWithOurCustomers #InariMedical Review complete Instructions for Use, Indications for Use, Warnings, Precautions, Possible Adverse Effects and Contraindications prior to use of the product. The information in this post is intended for healthcare professionals in the United States only.

We're excited to be attending the 29th European Vascular Course (EVC) in Maastricht this March! Join us for our hands-on workshop: "Don't let the clot settle: early intervention in acute DVT using AI and different clot removal techniques." Monday 9 March 2026 14:00-15:30 Room 0.2 During this interactive session, Dr. Marie Josee van Rijn, Vascular Surgeon at Erasmus Medical Centre (Rotterdam), will share her real-world experience in: - Patient selection for interventional treatment of acute #DVT - Mechanisms and technical considerations of mechanical thrombectomy - Acute DVT case studies and procedural strategy - Latest clinical evidence and emerging insights We look forward to connecting with peers and advancing the conversation on early intervention in DVT management. See you in Maastricht! #EVC2026 #Vascular #Thrombosis #MedicalInnovation #InterventionalRadiology Review complete Instructions for Use, Indications for Use, Warnings, Precautions, Possible Adverse Effects and Contraindications prior to use of the product. The information in this post is intended for healthcare professionals only.

Stent surveillance does more than detect failure — it guides why failure occurs. Patients with combined inflow disease had nearly 3× higher reintervention rates than those without inflow disease. Surveillance enables timely inflow assessment and targeted reintervention. More on #RevCore: bit.ly/3BgcvTp #RevCore #StentSurveillance #StentPatency #VenousIntervention Review complete Instructions for Use, Indications for Use, Warnings, Precautions, Possible Adverse Effects and Contraindications prior to use of the product. The information in this post is intended for healthcare professionals in the United States only.

The majority of venous in-stent thrombosis occurs within the first 6 weeks.* By one year, up to 90% of reinterventions have already occurred.* Surveillance protocols should prioritize early and routine duplex follow-up — not symptom-driven evaluation. More on #RevCore: bit.ly/3BgcvTp #RevCore #StentSurveillance #StentPatency #VenousIntervention *Gwozdz A. Eur J Endovascular Surg. 2018. Review complete Instructions for Use, Indications for Use, Warnings, Precautions, Possible Adverse Effects and Contraindications prior to use of the product. The information in this post is intended for healthcare professionals in the United States only.

#Surveillance Finds What Symptoms Miss: In a cohort of deep venous stent patients: • 41% required reintervention* • 87% were identified by duplex ultrasound surveillance* • Only 13% presented acutely with symptoms* Duplex surveillance detects stent failure long before patients do. More on #RevCore: bit.ly/3BgcvTp #RevCore #StentSurveillance #StentPatency #VenousIntervention *Gwozdz A. Eur J Endovascular Surg. 2018. Review complete Instructions for Use, Indications for Use, Warnings, Precautions, Possible Adverse Effects and Contraindications prior to use of the product. The information in this post is intended for healthcare professionals in the United States only.

We are excited to partner with @EVToday as Drs. Anahita Dua and Shang Loh share their experiences using Artix and talk about #ArtixASCEND. Offering mechanical, aspiration, proximal flow control, and blood return, Artix is truly an all-in-one system. Drs. Dua and Loh highlight how the over-the-wire design and flow arrest features have positively impacted their practices. Read the feature here: bit.ly/3OuATaJ Learn more about #Artix: bit.ly/42bzNFg Review complete Instructions for Use, Indications for Use, Warnings, Precautions, Possible Adverse Effects and Contraindications prior to use of the product. The information in this post is intended for healthcare professionals in the United States only.

Maintaining venous stent patency is highly dependent on inflow vessel quality. Patients without inflow disease experienced significantly lower reintervention rates compared to those with single or combined inflow disease. Identifying and addressing inflow issues early can change the reintervention trajectory. More on #RevCore: bit.ly/3BgcvTp #RevCore #StentSurveillance #StentPatency #VenousIntervention Review complete Instructions for Use, Indications for Use, Warnings, Precautions, Possible Adverse Effects and Contraindications prior to use of the product. The information in this post is intended for healthcare professionals in the United States only.

Early stent failure often goes undetected. New data shows that most primary venous stent patency loss occurs early — frequently before symptoms change. Residual thrombus, missed inflow disease, and anticoagulation challenges all contribute to silent failure. Stent surveillance isn’t optional — it’s foundational to long-term patency. More on #RevCore: bit.ly/3BgcvTp #RevCore #StentSurveillance #StentPatency #VenousIntervention Review complete Instructions for Use, Indications for Use, Warnings, Precautions, Possible Adverse Effects and Contraindications prior to use of the product. The information in this post is intended for healthcare professionals in the United States only.

Revisit the clinical conversation around #PEERLESS with The Clinical PE Story: PEERLESS RCT Comparing FlowTriever to CDT on VuMedi. In this educational session, leading interventional experts discuss trends in pulmonary embolism thrombectomy and review outcomes from the PEERLESS randomized trial comparing the FlowTriever® thrombectomy system with catheter-directed thrombolytics (CDT) in intermediate-risk PE patients. Watch the session here: bit.ly/4tX0F7N More on #FlowTriever: bit.ly/4dHrsfk #PulmonaryEmbolism #PEERLESS #FlowTriever #Thrombectomy #TogetherWithOurCustomers Review complete Instructions for Use, Indications for Use, Warnings, Precautions, Possible Adverse Effects and Contraindications prior to use of the product. The information in this post is intended for healthcare professionals in the United States only.

Building on the strong outcomes of the #FLAME study, the #PERSEVERE Randomized Controlled Trial is designed to address a critical evidence gap in the treatment of acute high-risk pulmonary embolism. By evaluating FlowTriever against standard of care in a randomized setting, this study seeks to advance evidence generation and inform the future of #PE management. Read the publication: bit.ly/40ds87j More on #FlowTriever: bit.ly/4dHrsfk #PulmonaryEmbolism #ClinicalTrials #FlowTriever #Cardiology #InterventionalMedicine #InariMedical #Stryker Review complete Instructions for Use, Indications for Use, Warnings, Precautions, Possible Adverse Effects and Contraindications prior to use of the product. The information in this post is intended for healthcare professionals in the United States only.

New Publication Alert! The study design and rationale for the #PERSEVERE Randomized Controlled Trial evaluating #FlowTriever vs. standard of care in high-risk pulmonary embolism has now been published in the American Heart Journal. This RCT is designed to evaluate if Large-Bore Mechanical Thrombectomy should be considered a first-line therapy for patients with acute high-risk PE. Read the publication: bit.ly/40ds87j More on #FlowTriever: bit.ly/4dHrsfk #PulmonaryEmbolism #ClinicalTrials #FlowTriever #Cardiology #InterventionalMedicine #InariMedical #Stryker Review complete Instructions for Use, Indications for Use, Warnings, Precautions, Possible Adverse Effects and Contraindications prior to use of the product. The information in this post is intended for healthcare professionals in the United States only.

#ICYMI: For a decade, FlowTriever has helped redefine PE treatment through innovation, performance, and clinical impact. And we’re just getting started. More on #FlowTriever: bit.ly/4dHrsfk Review complete Instructions for Use, Indications for Use, Warnings, Precautions, Possible Adverse Effects and Contraindications prior to use of the product. The information in this post is intended for healthcare professionals in the United States only.

We’re proud to invite you to Inari, now part of Stryker’s, sponsored breakfast symposium at #AVF2026! Join us for an engaging morning session titled From Evidence to Impact: Applying Long-Term DVT Data to Daily Practice, featuring Drs. Steven Abramowitz, Stephen Black, and Adam Gwozdz as they share insights on translating long-term DVT data into everyday venous practice. Tuesday, March 3 7:30 AM MT Sheraton Downtown Denver This symposium is a great opportunity to connect with leaders in the venous space and explore how evolving #DVT data is shaping treatment strategies, patient outcomes, and long-term care. #AVF2026 #VenousDisease #DVT #InariMedical #Stryker

The #InThrill® Thrombectomy System represents the next generation in flow restoration. Refined with direct physician feedback and built for performance, InThrill® is designed to deliver fast, effective clot removal in AV access and small-vessel thrombectomy. More on #InThrill®: bit.ly/45injM1 #DialysisAccess #Thrombectomy #InThrill #MedicalInnovation #NextGeneration The information in this post is intended for healthcare professionals in the United States only.

Redesigned with direct physician feedback, the #InThrill™ Thrombectomy System delivers faster, more effective clot removal and is helping raise the bar for performance-driven innovation in dialysis access care. More on #InThrill™: bit.ly/45injM1 #DialysisAccess #Thrombectomy #InThrill™ #MedicalInnovation #NextGeneration The information in this post is intended for healthcare professionals in the United States only.

The InThrill™ thrombectomy system—next generation technology designed for efficiency and built for results. More than performance, InThrill™ is focused on helping physicians restore blood flow quickly and supporting better outcomes for patients. By streamlining clot removal and optimizing procedural efficiency, it’s designed to get patients back to what matters most—faster. Check out more on #InThrill™: bit.ly/45injM1 #DialysisAccess #Thrombectomy #InThrill #MedicalInnovation #NextGeneration The information in this post is intended for healthcare professionals in the United States only.